We have another exciting profile we want you to research for Tuesday’s session.
This a company that we featured just last month.
Turn your attention to Nasdaq: BTCY.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets.
There is an ongoing shift in healthcare towards preventive care, which Biotricity is leveraging to modernize chronic care & disease management.
The company believes its diagnostic and post-diagnostic solutions help reduce healthcare costs and detect anomalies earlier than existing monitoring solutions and provide faster and better reporting, as well. BTCY has expanded its salesforce in 2022 and targets further penetration into doctor’s offices and clinics with the recent launch of Biotres and the upcoming launch of other products. The company believes its tech platform is disrupting the traditional cardiac care model. With Biotricity’stechnology, cardiac patients can access advanced diagnostics from their homes using Biotricity devices, and thereby minimize visits to the cardiologist or hospital to times when therapeutic treatment or procedures are needed. The company’s lead product, Bioflux, is designed to detect an arrhythmia, heart attack, ventricular or atrial issue faster and transmit the information to a call center to prevent a traumatic health event faster than a conventional Holter device.
As BTCY moves to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond the cardiac market. Biotricity believes its emerging ecosystem offers a user- friendly platform that can be applied to help people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas.
The company launched Biotres earlier this year. It is a wearable wireless 3-lead patch device for continuous recording of ECG heart data and wider array of arrythmia monitoring.
As BTCY initiatives measures to grow its share in the cardiac health cloud service niche, the company also seeks to expand horizontally beyond cardiac and believes its emerging ecosystem offers a user-friendly platform that can be applied to monitor and assist people suffering with diabetes, obesity, hypertension, sleep apnea, pain management and potentially many other areas of healthcare management.
Unveiled our personal medical device kit, Biokit, for integration into our Biotricity ecosystem
Unveiled, Bioheart, a first-of-its kind continuous heart rhythm recorder and personal heart and lifestyle solution
The Company’s Bioheart personal cardiac monitor won TIME’s Best Inventions of 2022.
Awarded $250K NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure.
Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib).
Launched Biocare Cardiac Disease Management Solution after two successful pilots at Oklahoma & Kentucky Clinics.
Continued expansion of our network and maintenance of a 95+% retention rate that together drive Biotricity’s residual revenues.
Operating Highlights for the Q3-FY23 to Date
Signed agreements with two leading US medical device distributors and one GPO
Net loss totaled $4.75 million, or $0.091 per share
Biotricity signs distribution agreement with top 5 distributor for its Cardiac Monitoring Solutions
REDWOOD CITY, Calif., Jan 26, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced it has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions (CMS) designed for cardiologists’ patient use – Bioflux® and BiotresTM.
The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients.
Commenting on the agreement, Biotricity Founder, Chairman and CEO Waqaas Al-Siddiq, Ph.D., said, “The future of healthcare lies with new, state-of-the-art technology that produces a more efficient and higher quality of care through remote care. That means tech that is specially designed for smart remote monitoring of individuals using digital/wireless and cloud-based technology with seamless integration with all platforms and devices.
“Our Bioflux and Biotres solutions address a market valued at $6 billion, and we fully expect to capture an increasing share of this growing marketplace,” Dr. Al-Siddiq added. “We are delivering cardiac care remotely, 24/7 and in real-time as needed, with technology that rivals existing standard of care solutions. Long term, we are confident our technology, and the lifestyle improvements it encourages will bend the curve of growing rates of heart disease.”
Biotricity’s Enviably Massive Addressable Markets According to the World Health Organization, Cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. We are determined to reduce that number in a meaningful way, as our growing success addresses a heart rate monitoring devices market of $12.4 billion globally that analysts project reaching $17.1 billion in 2026. As a company, our focus is on expanding our total addressable market (TAM) by executing on our product portfolio. This will increase our TAM from $1.7 for cardiac devices to $55.9 Billion for Telemedicine andvcare management. Suffice to say, we have an enourmous opportunity ahead, I believe these forecasts are low and do not yet factor in our technology’s superior capabilities and industry & patient health, wellness, and lower-cost benefits.
Cost Savings & Workflow Time Efficiency for Nurses. Instead of expensive hospitals and emergency room bills, pro-active monitoring and early detection of medicine need or surgery allows outpatient cost savings. Remote monitoring allows cost-effective at $11,000/year (NIH/Journal of Cardiovascular Electrophysiology) per patient year.
Reimbursement rates reduction or cut risk from Medicare is minimal exposure for Biotricity and its physicians network. Bioflux and the recently launched Biotres patch already fit into the existing billing codes and resilient clinical fee. Biotricity’s wheelhouse is more insulated because no reimbursement specialist is needed for billing and reads are insurance reimbursable.
Recurring revenue play and easily deployable tech. There is also lower operational expense for the doctors and clinics, along with easy integration into their back offices. Rechargeable devices help keep the margins high and further insulate from reimbursement.
Detection & Accuracy are improved with Bioflux compared to conventional products. Artificial Intelligence (AI) and Biotricity’s database on nearly 100,000 patients of ECG data can identify ECG abnormalities with 90%+ accuracy and speed up response time, according to BTCY.
Beneficiary of the ongoing shift to remote monitoring of outpatients and improved efficiency for doctors and nurses workflow. Physicians benefit from earlier detection of patient’s heart issues, improved workflow and efficiencies with Biotricity’s software and automation. The physician can increase their own annual revenues by approximately $180,000-260,000 as seen below.
Biotricity reports financial results for Fiscal 2023 Third Quarter
REDWOOD CITY, Calif., Feb 14, 2023 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced its financial results and provided a business update for its third quarter of fiscal 2023 ended December 31, 2022.
Commenting, Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “With our suite of state-of-the-art remote cardiac solutions now well established, Biotricity is focused on sales, marketing and achieving positive cash flow.
In just the past three months, we have successfully signed agreements with two leading US medical device distributors and one Group Purchasing Organization (GPO) as major components of our go-to market strategy and growing marketplace prominence. In total, just in the US alone, they cover over $20 billion in annual purchasing. We are actively considering adding similar distributors with geographic or vertical coverage that complement our existing networks.
“Technologically, we are increasingly leaning into AI with its data and predictive capability to target more pervasive forms of patient monitoring and lifestyle management. Our enviable 98 percent customer retention rate succinctly reflects our strong competitive position. It also ensures our customers’ lifetime value is high and drives our growing ‘technology-as-a-service’ base of recurring revenue.
“Financially, we reported strong sales revenue growth of 27.4 percent year-over-year, and a gross margin of 57 percent as our business scales, while narrowing the net loss by one third. In calendar year 2023, we plan to trim R&D and capex while continuing to innovate products and services centered around our cloud-based Biosphere cardiac ecosystem — to reduce the overall price of unrivaled cardiac care while positively transforming the efficacy of its delivery and outcomes.
“Looking ahead, we are focused on increasing market penetration through additional distribution agreements, highly targeted advertising, industry conference and tradeshow participation, and building our sales and marketing team one carefully selected professional at a time, all while managing cash flow to accelerate our path to profitability.”
Operating Highlights for the Q3-FY23 to Date
Signed agreements with two leading US medical device distributors and one GPO
Net loss totaled $4.75 million, or $0.091 per share
Full details of the Company’s financial results will be filed with the SEC on Form 10-Q, and are available at no cost by visiting www.sec.gov.
Financial Results Conference Call
Management will host a conference call on Tuesday, February 14, 2023 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://www.biotricity.com/investors/
Biotricity Product Roadmap
Bioflux® is their flagship product. It is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients’ ECG information.
Disruptive Business Model
Insourced business model, enabling physicians to bill directly
Minimal upfront cost for physician, physician pays only when device is used – top line profit
Turn-key solution for physicians
Recurring revenue with high margin for Biotricity
Reads are insurance reimbursable using existing CPT billing codes
Turn-key solution: device, software, and monitoring center • One piece device that is the smallest in the market
Built-in global GPS and GSM platform
CURRENT FOOTPRINT FOR BIOFLUX
Biotres is a three-lead patch solution for real-time and passive arrhythmia monitoring designed for patients who are at risk for, or diagnosed with, certain cardiac issues. It can operate as a Holter, Event Loop, and potentially as a wireless patch in conjunction with Bioflux for MCT. Biotres has been filed with the FDA and is pending approval.
Biocare® Telemed is a virtual clinic platform with secure HIPAA-compliant technology that enables clinicians to provide outstanding patient care remotely, ensuring their at-risk patients and those needing remote cardiac monitoring do not have to leave the safety and comfort of their home. Today, the Biocare app is used by our customer clinics to service their patients. Going forward, it will become a virtual cardiac clinic where individuals looking for a cardiologist will be able to access our network of cardiologists. To achieve this, we are currently interconnecting our customer clinics to create one large virtual cardiac clinic, which we expect to launch in the second half of 2022. This will enable individuals looking for a cardiologist to access one that uses the Biotricity eco-system of diagnostics and disease management technology. Biokit is a personal medical device kit, a bundled home-use set comprised of a digital thermometer, a pulse oximeter, and a blood pressure cuff. It is FDA cleared, wireless capable and readily integrates into the Biotricity eco-system. Introduced in September, it is slated for a 1Q-22 launch. With Bioflux and Biokit combined, we will soon offer a comprehensive cardiac diagnostics and management product line for effective, accurate and economic long-term disease management.
Bioheart is for consumers seeking self-management of pre-diagnosis heart health, wellness and preventative care. Consumers can share data with their physicians if they choose. Following strong sales during its pre-release period, we launched Bioheart earlier this month – ahead of schedule – and plan to ramp up its marketing campaign throughout 2022.
Biotricity surpasses $10 million in annual revenue run rate
REDWOOD CITY, Calif., Nov 21, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced it has surpassed $10 million in annual revenue run rate. “With strong revenue growth each quarter, our scale and market reach increases every day,” says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq. “I am committed to continuing to drive growth and realize our potential. Our focus remains on providing the cardiac health market with disruptive, superior digital and AI technology at competitive pricing with unrivaled support to our customers and physician partnerships.” Biotricity boasts multiple ground-breaking products including Bioflux®, Biotres, and Bioheart which won TIME’s Best Inventions of 2022.
Bioflux: a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of your ECG information to your doctor
Biotres: an easy to wear, rechargeable device with wireless capability, utilizing the advanced technology of the Bioflux® for more active days
Bioheart: a consumer-targeted continuous heart rhythm monitor that uses the most advanced heart technology to deliver unlimited heart data insights with three views of your heart
The record revenue run rate is Biotricity’s latest achievement in a string of major milestones that include:
The Company’s Bioheart personal cardiac monitor won TIME’s Best Inventions of 2022
Awarded $250K NIH grant from the National Heart, Blood, and Lung Institute for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure
Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation (A-fib)
Company has delivered revenue growth in nine out of the last ten consecutive quarters
Biotricity’s Bioheart named to TIME’s list of The Best Inventions of 2022
Bioheart provides consumers the most advanced personal heart monitoring technology, combining powerful analytics and continuous heart monitoring for personalized heart insights
November 10, 2022 | REDWOOD CITY, Calif., Nov 10, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that its Bioheart device has been named to TIME’s list of the Best Inventions of 2022. Bioheart is the first of its kind – a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.
Cardiac issues are intermittent, often asymptomatic, and lifelong in nature, requiring continuous heart activity monitoring. Fitness trackers simply collect your heart rate and personal ECG devices manually collect a few minutes of data, leaving you without the full picture. Bioheart changes everything by creating the first heart activity monitor. Whether you are sleeping, sitting, or out exploring the world, Bioheart’s uninterrupted monitoring keeps you informed about your heart 24/7. TIME reveals its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives: time.com/best-inventions-2022. To compile the list, TIME solicited nominations from TIME’s editors and correspondents around the world, as well as through an online application process, paying special attention to growing fields-such as the electric vehicle industry, green energy, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. Of the New Best Inventions list, TIME’s editors wrote: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)- including life-mapping artificial intelligence, diamonds made from excess carbon in the air, and the most powerful telescope ever-that are changing how we live, work, play, and think about what’s possible.” “We are honored and excited to have our premier consumer product, Bioheart, included in TIME’s 2022 list,” commented Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our mission is to disrupt and transform the state of cardiac health and wellness, worldwide. Bioheart is the beginning of this journey”
There are several analysts with price targets on BTCY well above it’s current levels of a dollar. They all represent 300%+ moves from it’s current levels if the analysts turn out to be right.
Biotricity surpasses 2 billion recorded and analyzed heartbeats for atrial fibrillation (AFib)
Data set of 2 billion heartbeats and growing allows Biotricity to scale faster and operate more efficiently with better automation, yielding growth and better margins in the future
REDWOOD CITY, Calif., Oct 04, 2022 (ACCESSWIRE) — Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient’s ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux’s built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI). Leveraging the Company’s proprietary AI, over 2 billion of the total heartbeats to date have been segmented for AFib analysis. According to Emergen Research, the global recurrent market for AFib is expected to reach USD$26 billion by 2027, growing at a CAGR of 13.2%. This large data set provides further benefits for patients, providers and ultimately clinical research for the future of predictive monitoring. Additionally, it allows Biotricity to scale faster and operate more efficiently, develop better automation, yielding growth and better margins in the future. The consistent focus on R&D and data capture has positioned Biotricity with a significant competitive advantage in key cardiac segments of the market, such as AFib. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “AFib unfortunately continues to be a leading cardiac risk globally, growing annually at alarming rates. We have purposely designed our ecosystem to monitor the patient 24/7 while leveraging our innovative technology that uniquely combines AI with data and predictive capabilities. In doing so, we can create better and faster analytics for preventative patient monitoring and lifestyle management. For AFib specifically, the ability to significantly narrow the time of diagnosis reduces risk for the patient and liability for the provider, giving our technology the ability to positively impact millions who suffer with AFib globally. Additionally, as we continue to collect more data through our R&D efforts, our internal quality review process will scale and further increase in efficiency, allowing us to continue to grow our margins.”
Dr. Waqaas Al-Siddiq, Phd
Chairman, CEO & Founder
Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council. Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technical and academic world. Coupled with this, Waqaas has vast experience in leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and non-profits. Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration from Henley Business School. He also holds a Doctorate in Business with a specialty in Transformative Innovations and Billion Dollar Markets.
Norman Betts, Phd
Independent Board Member
Norman sits on the Boards of Directors of the Bank of Canada, Tembec Inc., New Brunswick Power Corporation, 49 North Resources Inc., Adex Mining Inc., Tanzanian Royalty Exploration Inc. and the University of New Brunswick Pension Plan for Academic Employees. Norman is an Associate Professor in the Faculty of Business Administration at the University of New Brunswick in Fredericton. He is accomplished in the field of accounting and finance, with a mix of academic, public, and private-sector experience. He is an expert in accounting regulations, and has extensive experience in audits, risk management, governance and oversight. He was a member of the New Brunswick Legislative Assembly from 1993 to 2003 and held three different cabinet posts, including Minister of Finance from 1999 to 2001. Prior to entering politics, Norman was Assistant Dean of the MBA Programme and an Associate Professor at the University of New Brunswick as well as a partner in the accounting firm Shannon, Betts & Buffett. Norman received a PhD in Management with a concentration in accounting and finance from Queen’s University School of Business in 1992 and a Bachelor of Business Administration from the University of New Brunswick in 1978. He also holds a Fellow Chartered Accountant designation.
Independent Board Member
Dave has spent the past 22 years in a variety of positions in the medical device industry. He was appointed CEO of Sunshine Heart in October of 2009 and served as President and Chief Executive Officer through November 2015. Dave took Sunshine Heart Public on NASDAQ in 2012 and raised over $120M during his tenure. The Company achieved a number of clinical, regulatory and research and development milestones under his leadership. Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Dave was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he developed the strategic pan for the newly formed interventional division, directed the launch of several new products and oversaw the acquisition and integration of Velocimed, a privately held company in the cardiovascular space. From 1999-2004, Dave held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that developed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, Dave served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific. Dave holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.
Independent Board Member
Patricia has spent over 25 years in a variety of global sales and distribution positions in the medical device industry, focusing on the field of Electrophysiology. In 2015, she founded and is currently the Managing Director of PJM Medical Consultants, supporting medical device companies entering the international market with market entry and product commercialization strategies. From 2008 to 2015, Pat served as VP – International and General Manager for Atricure, Inc. She achieved significant sales, market development and clinical science milestones, while defining strategic plans and pursuing technology development and acquisitions. From 2001 to 2008, Pat worked with Stereotaxis, Inc. in numerous executive positions including Worldwide VP – Clinical Services and VP – International Sales and Marketing. Prior to Stereotaxis, Pat worked with EP MedSystems as International Marketing Manager for defibrillation and diagnostic catheters. She began her career in the medical industry at Boston Scientific from 1992 to 1997 while serving in several positions, including Sales and International Product Manager for EPT. Pat has earned a Bachelor of Science Degree in Marketing from the University of Florida and a Bachelor of Science in Nursing degree from the University of North Florida.
Independent Board Member
Steve Salmon has expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners, where he managed a number of portfolio companies. Prior to becoming a VC, Mr. Salmon was a founder of Ensure Medical and Integrated Vascular Systems, both of which were successfully exited through acquisition. He also served as the CEO of Revascular which was also acquired. Mr. Salmon brings to Biotricity his deep expertise in raising capital, facilitating growth, and driving long term value.
Chief Financial Officer
John has over 25 years of accounting, finance, and operations experience, having previously served as CFO of several public companies and a regulated financial institution. As CFO of Equitable Group, Mr. Ayanoglou raised over $130 million of regulatory capital in common, preferred, and debenture offerings over successive transactions, all during a period of extreme capital market turbulence, helping to successfully grow assets under administration from $6.1 billion to over $10 billion to facilitate Equitable Bank in becoming Canada’s ninth largest bank. He was also the CFO and Corporate Secretary of Xceed Mortgage Corporation, where he partnered with an entrepreneurial top team to grow the business through the successful implementation of warehouse financing lines and other securitization programs including public term securitizations of over $700 million. John has extensive experience as a trusted business advisor working with management teams and boards on business acquisition and consolidation, risk mitigation and turnaround, to establish efficient, effective operations. He is a CA, CPA with a Bachelor of Commerce degree in Finance and Economics from the University of Toronto and his ICD.D designation from the Institute of Corporate Directors and the Rotman School of Business.
Chief Development Officer
Amir is a serial entrepreneur with over 20 years of experience in launching companies and producing innovative products, services, and solutions. Amir is sought after for his expertise in transforming R&D technologies into products based on market needs, commercializing products for volume production, and establishing global distribution channels across the world. Prior to joining Biotricity, Amir served as CEO at AT Labs Inc., where his team pioneered the concept of wireless mobile thin clients to access secure enterprise applications through the cloud. The efficacy of the robust solutions resulted in customers from healthcare, government, enterprise, and retail sectors, most of which spanned thousands of locations across the United States. His experience in developing such novel technologies has put him at the forefront of companies that have grown in revenue from zero to over $160 million. In his own ventures, he has worked with many leading industrial and financial institutional funders including Jafo, Bay Partners, and JP Morgan with whom he has raised over $35 million.
Vice President, Engineering
Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. Spencer obtained his undergraduate degree while balancing a full-time job at Flightline Systems Ultra Electronics, a small defense contractor. His specialties are in the design and implementation of radio frequency, digital, analog, embedded software and PC software. Spencer also has experience in working with marketing, sales, and manufacturing teams in order to develop products for large-scale output. Spencer has a Bachelor’s degree in Computer Engineering from Rochester Institute of Technology.
Thomas C. Nelson
Nelson serves as the president of Share Our Strength, a national nonprofit that is ending childhood hunger in America. Prior to joining Share Our Strength in 2011, Nelson was chief operating officer for AARP, where he led the build-out of its state strategy in all 53 US states and territories. In addition to serving as an adjunct professor at Georgetown University’s McDonough School of Business, Nelson has a long history of service to civic organizations, including his current position on the board of directors of ProInspire. Other board positions include, the board of counselors for the Davis Gerontology School at the University of Southern California; the board of the Certified Financial Planner Board of Standards; and the board of Community Wealth Partners. Nelson holds a Ph.D. from the University of Southern California and an M.A. from Columbia University.
John Rother, JD
Mr. Rother is President and CEO of the National Coalition on Health Care, America’s oldest and most diverse group working to achieve comprehensive health system change. Prior to joining the Coalition in 2011, Rother worked at AARP for over 27 years as the Executive Vice President for Policy, Strategy, and International Affairs where he led the development of AARP’s policy positions and advocacy strategies. Under his leadership, AARP engaged in public policy research and analysis, public education, and advocacy on health and retirement issues at the federal, state and international levels. Rother wrote numerous articles and was a frequent speaker on health, retirement security, the federal budget, and the boomer generation. Prior to that, Rother was Staff Director and Chief Counsel for the U.S. Senate Special Committee on Aging under the direction of Chairman John Heinz and served as Special Counsel for Labor and Health to U.S. Senator Jacob Javits. He has consistently been named as one of the most powerful people in Healthcare and in 2010 received the Robert Ball Award for Outstanding Achievements in Social Insurance from the National Academy of Social Insurance for “lifetime advocacy to strengthen Social Security and Medicare.”
Daniel Sands, MD, MPH
Dr. Sands is passionate about healthcare transformation, non-visit based care, collaboration in healthcare, and participatory medicine. He spent six years at Cisco, as chief medical informatics officer, where he provided both internal and external health IT leadership and helped key customers with business and clinical transformation using IT. Sands’ prior position was chief medical officer for Zix Corporation, a leader in secure e-mail and e-prescribing. Sands also spent 13 years at Beth Israel Deaconess Medical Center in Boston, where he developed and implemented numerous systems to improve clinical care delivery and patient engagement. He has earned degrees from Brown University, Ohio State University and the Harvard School of Public Health, and trained at Boston City Hospital and Boston’s Beth Israel Hospital. Sands currently holds an academic appointment at Harvard Medical School and maintains a primary care practice in which he makes extensive use of health IT. He works as a consultant for a variety of innovative companies. Sands is the recipient of numerous health IT awards, has been elected to fellowship in both the American College of Physicians and the American College of Medical Informatics, and is a founder and co-chair of the board of the Society for Participatory Medicine. In 2009, he was recognized by HealthLeaders Magazine as one of “20 People Who Make Healthcare Better.”
THIS WEBSITE/NEWSLETTER IS A WHOLLY OWNED SUBSIDIARY OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22, LLC
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FOURTEEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LEGENDS MEDIA, LLC FOR A ONE DAY BTCY AWARENESS CAMPAIGN.WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF ONE HUNDRED AND TEN THOUSAND FIVE HUNDRED USD FOR SIX PREVIOUS BTCY AWARENESS CAMPAIGNS BY THE SAME THIRD PARTY, LEGENDS MEDIA, LLC. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: O22 LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD O22, LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND O22, LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD O22, LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.O22, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. O22, LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND O22, LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.IN PREPARING THIS PUBLICATION,O22, LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, O22, LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. O22, LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS O22, LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. 022, LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.